Virion Therapeutics, LLC Announces the Appointment of Sue Currie, Ph.D. as Chief Operating Officer Philadelphia PA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developer of immunotherapies for cancer and chronic infectious diseases that utilize genetically encoded checkpoint...

Virion Therapeutics, LLC Announces the Appointment of M. Michelle Berrey, M.D., M.P.H. and Williamson Bradford, M.D., Ph.D. to Its Board of Directors Philadelphia PA, July 12, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developer of T cell-based immunotherapies that utilize the first genetically encoded checkpoint inhibitor today...

Virion Therapeutics Presents Data Showing Enhanced and Sustained Virus Declines in Animals upon Immunization with VRON-0200, a Therapeutic Vaccine for Chronic Hepatitis B Virus (HBV) Infections at the International Liver Congress (ILC) Philadelphia PA, June 25, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developer of T cell-based immunotherapies that utilize the first genetically encoded checkpoint inhibitor, today...

Virion Therapeutics Announces Presentation of Preclinical Data of VRON-0200, a Chronic Hepatitis B Virus (HBV) Therapeutic Vaccine, at the International Liver Congress (ILC) Philadelphia PA, June 21, 2021 (GLOBE NEWSWIRE) -- Virion Therapeutics, LLC, developers of T cell-based immunotherapies that utilize the first genetically encoded checkpoint inhibitor, today...